NCNA — NuCana plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1709626 ·
Last close
$1.28
Market Cap
$5.33M
52W High
$7.22
52W Low
$1.21
ADV30
69,650
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,437,000 | -3,080,000 | 25,783,000 | 19,503,000 | 5,523,000 |
| Mar 2026 | 0 | — | -4,781,000 | -3,865,000 | 27,553,000 | 21,529,000 | 5,186,000 |
| Dec 2025 | 0 | — | -2,843,000 | -2,485,000 | 29,834,000 | 24,251,000 | 5,507,000 |
| Sep 2025 | 0 | — | -3,571,000 | -281,000 | 32,315,000 | 25,249,000 | 6,389,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,540,000
Investing CF
$242,000
Financing CF
$24,557,000
CapEx
$-231,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-251,172,000
Inventory
—
Receivables
$3,037,000
ST Investments
—
EBIT TTM
$-22,822,000
Pretax Income TTM
$-31,970,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,833,000 | -29,353,000 | 29,834,000 | 5,507,000 | 24,327,000 | -7,467,000 |
| Dec 2024 | 0 | -23,005,000 | -18,997,000 | 14,774,000 | 8,820,000 | 5,954,000 | -19,118,000 |
| Dec 2023 | 0 | -31,125,000 | -27,632,000 | 27,811,000 | 12,924,000 | 14,887,000 | -26,439,000 |
| Dec 2022 | 0 | -43,717,000 | -32,021,000 | 58,254,000 | 19,752,000 | 38,502,000 | -23,158,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-9.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.41M | $2.20 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $5.14M | $1.84 | — |
| INBP | INTEGRATED BIOPHARMA INC | $5.59M | $0.18 | — |
| XBIO | Xenetic Biosciences, Inc. | $5.60M | $2.39 | — |
| DRMA | Dermata Therapeutics, Inc. | $5.65M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:01 · Yahoo
NuCana Appoints Ian Webster as Chief Financial Officer
2026-06-01 12:00 · Yahoo
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 20:01 · Yahoo
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
2026-04-16 15:05 · Yahoo
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
2026-03-19 20:01 · Yahoo
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
2026-02-24 16:03 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week
2026-02-06 16:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-02-04 16:13 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading
2026-01-13 16:10 · Yahoo
NuCana Appoints Theresa Bruce as Chief Operating Officer
2026-01-06 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.